Mainstream

AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook

AstraZeneca beats top-line and bottom-line estimates; reaffirms FY25 outlook

Post Contentazn, azncfRead More

You might also be interested in reading Bitcoin Price Makes Another Run at $100K as U.S. Traders Return After Thanksgiving.

July 29, 2025
In Mainstream